Krystal Biotech stock forecast
Krystal Biotech (4KB) Stock Forecast & Price Target
4KB Analyst Ratings
4KB Stock 12 Month Forecast
Average Price Target
€355.39▲(29.23% Upside)Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Lisa Walter | RBC Capital | €338.97 | buy | 23.26%Upside | Reiterated | 11/06/26 | ||
| Yigal Nochomovitz | Citi | €376.03→€372.42 | buy | 35.43%Upside | Reiterated | 11/03/26 | ||
| Ritu Baral | TD Cowen | €364.28→€343.49 | buy | 24.91%Upside | Reiterated | 11/03/26 | ||
| Joseph Pantginis | H.C. Wainwright | €326.32 | buy | 18.66%Upside | Reiterated | 11/02/26 | ||
| Alec Stranahan | Bank of America Securities | €361.57→€352.53 | buy | 28.19%Upside | Reiterated | 11/02/26 | ||
| Andrea Newkirk | Goldman Sachs | €398.63 | buy | 44.96%Upside | Initiated | 09/24/26 | ||
| Kalpit Patel | Wolfe Research | ― | hold | ― | Reiterated | 08/11/26 | ||
| Sami Corwin | William Blair | ― | buy | ― | Reiterated | 08/03/26 | ||
| Roger Song | Jefferies | €428.46 | buy | 55.80%Upside | Assigned | 07/13/26 | ||
| Gavin Clark-Gartner | Evercore ISI | €266.66→€271.18 | buy | -1.39%Downside | Reiterated | 05/05/26 | ||
| William Maughan | Clear Street | €305.53→€281.12 | buy | 2.23%Upside | Reiterated | 05/04/26 | ||
| Geulah Livshits | Chardan Capital | €291.97 | buy | 6.17%Upside | Reiterated | 05/04/26 | ||
| Debjit Chattopadhyay | Guggenheim | €256.72 | buy | -6.65%Downside | Reiterated | 05/04/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Lisa WalterRBC Capital | BuyReiterated€338.97 | 11/06/26 | 23.26%Upside | ||
| Yigal NochomovitzCiti | BuyReiterated€376.03→€372.42 | 11/03/26 | 35.43%Upside | ||
| Ritu BaralTD Cowen | BuyReiterated€364.28→€343.49 | 11/03/26 | 24.91%Upside | ||
| Joseph PantginisH.C. Wainwright | BuyReiterated€326.32 | 11/02/26 | 18.66%Upside | ||
| Alec StranahanBank of America Securities | BuyReiterated€361.57→€352.53 | 11/02/26 | 28.19%Upside | ||
| Andrea NewkirkGoldman Sachs | BuyInitiated€398.63 | 09/24/26 | 44.96%Upside | ||
| Kalpit PatelWolfe Research | HoldReiterated | 08/11/26 | ― | ||
| Sami CorwinWilliam Blair | BuyReiterated | 08/03/26 | ― | ||
| Roger SongJefferies | BuyAssigned€428.46 | 07/13/26 | 55.80%Upside | ||
| Gavin Clark-GartnerEvercore ISI | BuyReiterated€266.66→€271.18 | 05/05/26 | -1.39%Downside | ||
| William MaughanClear Street | BuyReiterated€305.53→€281.12 | 05/04/26 | 2.23%Upside | ||
| Geulah LivshitsChardan Capital | BuyReiterated€291.97 | 05/04/26 | 6.17%Upside | ||
| Debjit ChattopadhyayGuggenheim | BuyReiterated€256.72 | 05/04/26 | -6.65%Downside |
Best Analysts Covering Krystal Biotech
Copying Geulah Livshits's trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +11.04% per trade.
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +47.67% per trade.
Copying Geulah Livshits's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +92.75% per trade.
4KB Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 20 | 12 | 11 | 12 | 12 |
| Hold | 0 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 20 | 13 | 12 | 13 | 12 |
In the current month, 4KB has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 4KB average Analyst price target in the past 3 months is 355.39.
4KB Financial Forecast
4KB Earnings Forecast
Next quarter’s earnings estimate for 4KB is EUR 1.83 with a range of EUR 1.61 to EUR 2.17. The previous quarter’s EPS was EUR 1.84. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
4KB Sales Forecast
Next quarter’s sales forecast for 4KB is EUR 120.19M with a range of EUR 116.28M to EUR 123.08M. The previous quarter’s sales results were EUR 114.20M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

